Clara Biotech, Inc. is a Kansas City based biotechnology company building an exosome isolation and purification platform that solves a huge roadblock in exosome harvesting. Clara’s ExoRelease™ technology has the potential to enable the biopharma industry to create future breakthrough medicines with the purity, potency, safety and high quality desired by Regulatory Authorities. Clara provides biopharma companies a path to solve the major problem in exosomes today - purification. The Company’s first product, ExoRelease Exosome Isolation Kit allows researchers to isolate and purify exosomes from any fluid (e.g. plasma, cell culture media, urine, etc) in their own lab. An Early Access Program (EAP) is currently underway with customers in North America, Europe, Africa, and Asia. Clara is pursuing early steps in therapeutic exosome development for both manufacturing and preclinical assessment, and is pursuing partners to drive these activities.
Clara Biotech is presenting as a part of the NIH Innovation Zone.
